A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)

This study is for adults, aged 18 or older, who have been diagnosed with multiple myeloma. Your cancer must have previously been treated with one or two different types of therapy, but it either came back or didn't get better after those treatments. You also need to be generally well enough to take part in a study, as assessed by your doctor.

To join, your multiple myeloma must still be 'measurable', meaning doctors can track its progress through certain blood or urine tests. If you've had a stem cell transplant in the past, that's okay, but it must have been more than 100 days ago and you shouldn't have any active infections. Any side effects from your previous treatments must also have mostly cleared up, or only be very mild, except for hair loss.

There are also requirements concerning organ function, which will be checked by blood tests, and strict contraception rules for both men and women to prevent pregnancy during the study.

If you join this study, you'll receive the study treatment, which involves belantamab mafodotin given less often alongside other standard cancer medicines. You will have regular visits to the clinic for medical examinations, blood tests, and other assessments to check your health, how the treatment is working, and if you are experiencing any side effects. You'll also need to follow strict contraception rules throughout the study period. The total duration of your participation will depend on how you respond to the treatment and the study plan, but you will be monitored closely throughout.